Search hospitals > California > Fresno

Fresno Cancer Center

Claim this profile
Fresno, California 93720
Global Leader in Breast Cancer
Conducts research for Prostate Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
81 reported clinical trials
6 medical researchers
Photo of Fresno Cancer Center in FresnoPhoto of Fresno Cancer Center in FresnoPhoto of Fresno Cancer Center in Fresno

Summary

Fresno Cancer Center is a medical facility located in Fresno, California. This center is recognized for care of Breast Cancer, Prostate Cancer, Lung Cancer, Breast cancer, Cancer and other specialties. Fresno Cancer Center is involved with conducting 81 clinical trials across 142 conditions. There are 6 research doctors associated with this hospital, such as Jennifer M. Suga, Tatjana Kolevska, MD, Samantha A. Seaward, and Natalya Greyz-Yusupov.

Area of expertise

1Breast Cancer
Global Leader
Fresno Cancer Center has run 19 trials for Breast Cancer. Some of their research focus areas include:
Stage I
Stage II
Stage III
2Prostate Cancer
Fresno Cancer Center has run 10 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at Fresno Cancer Center

Breast Cancer
Ovarian Cancer
Prostate Cancer
Cutaneous Melanoma
Esophageal cancer
Lung Cancer
Melanoma
Cancer
Esophageal Adenocarcinoma
Gastric cancer
Image of trial facility.

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Fresno Cancer Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security